Determinants for Neoantigen Identification

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Tumors accumulate genetic alterations, leading to mutated peptides (neoantigens) presented by human leukocyte antigen (HLA) molecules.
• Neoantigens are tumor-specific and elicit T-cell responses, playing a key role in cancer immunotherapy effectiveness.
• Targeting neoantigens via vaccines and adoptive T-cell therapies is a promising strategy, but their identification is challenging.

Purpose of the Study:

• To provide an overview of current strategies for identifying personalized neoantigens in cancer patients.
• To evaluate the strengths and limitations of different methods for assessing neoantigen immunogenicity.
• To guide researchers in selecting appropriate methods for neoantigen identification in their specific laboratory settings.

Main Methods:

• Review of existing computational and experimental strategies for neoantigen prediction.
• Analysis of methods used to assess the immunogenicity of candidate neoantigens.
• Comparative evaluation of different approaches based on their strengths and limitations.

Main Results:

• Only a small fraction of tumor somatic non-synonymous mutations (NSM) are true neoantigens.
• Systematic identification of personalized neoantigens remains a significant challenge.
• Various methods exist for neoantigen identification and immunogenicity evaluation, each with specific advantages and disadvantages.

Conclusions:

• Rationally selecting and applying the most suitable neoantigen identification and immunogenicity assessment methods is critical for successful cancer immunotherapy.
• Further development and validation of robust neoantigen discovery pipelines are needed.
• Understanding the nuances of different methodologies will accelerate the clinical application of neoantigen-targeted therapies.